+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032- Product Image
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032- Product Image
New

Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888133
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The glioblastoma multiforme treatment market is undergoing significant transformation, driven by scientific advances, operational shifts, and multidisciplinary clinical approaches. Strategic understanding is key for executives aiming to capitalize on innovation while navigating regulatory, economic, and supply-chain complexities.

Market Snapshot

The Glioblastoma Multiforme Treatment Market grew from USD 3.65 billion in 2025 to USD 3.97 billion in 2026 and is projected to reach USD 6.41 billion by 2032 at a CAGR of 8.35%. Market growth is propelled by integrated care, precision medicine, and the adoption of new modalities, with evolving patient needs and regulatory landscapes shaping procurement and delivery strategies.

Scope & Segmentation

This report provides granular analysis of the glioblastoma multiforme treatment market across technology, therapeutic class, care setting, and region, enabling informed strategic planning.

  • Treatment Modalities: Drug Therapy, Radiotherapy, Surgical Interventions, Supportive Care
  • Therapeutic Classes: Chemotherapy, Gene Therapy, Immunotherapy, Targeted Therapy
  • Key Agents: Carmustine, Temozolomide, Checkpoint Inhibitors, Monoclonal Antibodies, Oncolytic Virus Therapies, Vaccine Therapies
  • Radiotherapy Techniques: Brachytherapy, External Beam, Radiosurgery
  • Supportive Care: Antiepileptic Drugs, Corticosteroids
  • Surgical Approaches: Biopsies, Craniotomy, Minimally Invasive Procedures
  • Lines of Therapy: First-Line, Second-Line, Third-Line
  • End Users: Home Healthcare, Hospitals, Research Institutes, Specialty Clinics
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Regions Analyzed: Americas, Europe, Middle East & Africa, Asia-Pacific

Key technologies such as molecular diagnostics, genomic and epigenomic profiling, and real-world analytics underpin evidence-based segmentation. Regional assessment addresses infrastructure contrasts, clinical adoption, and supply chain strengths.

Key Takeaways

  • Multidisciplinary care increasingly aligns neurosurgery, neuro-oncology, radiotherapy, and support services to optimize patient outcomes.
  • Molecular diagnostics and companion testing drive personalized therapeutic strategies, enabling precise patient subgroup identification and tailored regimens.
  • Emergent therapies, including checkpoint blockade, vaccine platforms, cell-based therapies, and gene-editing, are reshaping trial designs and accelerating bench-to-bedside transition.
  • Advanced surgical and radiotherapy technologies support improved local control while emphasizing neurologic preservation and post-treatment quality of life.
  • Regional infrastructure, payer alignment, and care delivery models are key to translating innovation into accessible care, requiring tailored value communication.
  • Strategic partnerships with academic and clinical centers facilitate rapid clinical validation and scalable evidence generation.

Tariff Impact

Recent U.S. tariff adjustments have affected global healthcare supply chains, impacting procurement costs for pharmaceutical components, radiotherapy equipment, and specialized medical devices. These costs influence hospital sourcing decisions, production localization, and clinical development economics. Higher tariffs on imported research inputs have led stakeholders to reevaluate manufacturing networks, structure long-term supplier agreements, and deepen regional partnerships to strengthen supply resilience. Strategic supply diversification and scenario planning are recommended to address the operational risks associated with shifting trade policy environments.

Methodology & Data Sources

This executive analysis synthesizes peer-reviewed clinical literature, clinical trial registries, regulatory filings, technical white papers, and expert interviews across relevant specialties. Data triangulation ensures clinical accuracy, while methodological limitations, such as potential publication lag and practice variance, are clearly disclosed. Where direct measurement is constrained, the report emphasizes actionable capability insights and operational implications over estimates.

Why This Report Matters

  • Enables senior decision-makers to anticipate shifts in the glioblastoma multiforme treatment market through up-to-date, segment-specific intelligence.
  • Supports risk-mitigation and investment with actionable analysis on regulatory, economic, and operational drivers across regions and supply chains.
  • Facilitates alignment of clinical and commercial strategy, ensuring that innovation translates into enhanced patient access and market sustainability.

Conclusion

Scientific progress, adaptive delivery models, and operational readiness must converge to meet evolving patient and market needs in glioblastoma care. Aligning clinical and commercial priorities will support equitable innovation and sustainable growth across the global treatment landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Glioblastoma Multiforme Treatment Market, by Treatment Type
8.1. Drug Therapy
8.1.1. Chemotherapy
8.1.1.1. Carmustine
8.1.1.2. Combination Chemotherapy
8.1.1.3. Temozolomide
8.1.2. Gene Therapy
8.1.2.1. Gene Editing
8.1.2.2. Oncolytic Virus Therapy
8.1.3. Immunotherapy
8.1.3.1. Checkpoint Inhibitors
8.1.3.2. Vaccines
8.1.4. Targeted Therapy
8.1.4.1. Bevacizumab
8.1.4.2. EGFR Inhibitors
8.2. Radiotherapy
8.2.1. Brachytherapy
8.2.2. External Beam Radiotherapy
8.2.3. Radiosurgery
8.3. Supportive Care
8.3.1. Antiepileptic Drugs
8.3.2. Corticosteroids
8.4. Surgical
8.4.1. Biopsy Procedures
8.4.2. Craniotomy
9. Glioblastoma Multiforme Treatment Market, by Drug Class
9.1. Alkylating Agents
9.1.1. Carmustine
9.1.2. Temozolomide
9.2. Checkpoint Inhibitors
9.2.1. Nivolumab
9.2.2. Pembrolizumab
9.3. Monoclonal Antibodies
9.4. Oncolytic Virus Therapies
9.5. Vaccine Therapies
9.5.1. Dendritic Cell Vaccines
9.5.2. Peptide Vaccines
10. Glioblastoma Multiforme Treatment Market, by Line Of Therapy
10.1. First Line
10.2. Second Line
10.3. Third Line
11. Glioblastoma Multiforme Treatment Market, by End User
11.1. Home Healthcare
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics
12. Glioblastoma Multiforme Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Glioblastoma Multiforme Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Glioblastoma Multiforme Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Glioblastoma Multiforme Treatment Market
16. China Glioblastoma Multiforme Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AIVITA Biomedical, Inc.
17.6. Angiochem Inc.
17.7. Avant Immunotherapeutics, Inc.
17.8. Bayer AG
17.9. Chimerix Inc.
17.10. Daiichi Sankyo Company, Limited
17.11. Diffusion Pharmaceuticals Inc.
17.12. DNAtrix, Inc.
17.13. Eisai Co., Ltd.
17.14. F. Hoffmann-La Roche Ltd
17.15. Karyopharm Therapeutics Inc.
17.16. Kazia Therapeutics Limited
17.17. Lineage Cell Therapeutics, Inc.
17.18. Merck & Co. Inc.
17.19. Moleculin Biotech, Inc.
17.20. Novocure GmbH
17.21. OncoSynergy, Inc.
17.22. Pfizer Inc.
17.23. Sapience Therapeutics, Inc.
17.24. SonALAsense
17.25. Sumitomo Dainippon Pharma Oncology, Inc.
17.26. Sun Pharmaceutical Industries Ltd.
17.27. Teva Pharmaceutical Industries Ltd.
17.28. VBI Vaccines Inc.
17.29. VBL Therapeutics
List of Figures
FIGURE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 210. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 211. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 212. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 213. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 214. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 215. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 216. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 217. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 218. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 220. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 222. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 223. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 242. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 243. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 244. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 245. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 246. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 247. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 248. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 249. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 250. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 251. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 252. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 253. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 254. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 255. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 263. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 264. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 265. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 266. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 273. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 275. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
TABLE 276. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 277. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 278. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 279. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 280. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 281. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 282. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
TABLE 283. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 284. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
TABLE 285. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABL

Companies Mentioned

The key companies profiled in this Glioblastoma Multiforme Treatment market report include:
  • AIVITA Biomedical, Inc.
  • Angiochem Inc.
  • Avant Immunotherapeutics, Inc.
  • Bayer AG
  • Chimerix Inc.
  • Daiichi Sankyo Company, Limited
  • Diffusion Pharmaceuticals Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lineage Cell Therapeutics, Inc.
  • Merck & Co. Inc.
  • Moleculin Biotech, Inc.
  • Novocure GmbH
  • OncoSynergy, Inc.
  • Pfizer Inc.
  • Sapience Therapeutics, Inc.
  • SonALAsense
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBI Vaccines Inc.
  • VBL Therapeutics

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.97 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.41 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market Forecast to 2033 - Product Image

Glioblastoma Multiforme Treatment Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report - Product Image

Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market Report by Drug Type, and Region 2025-2033 - Product Image

Glioblastoma Multiforme Treatment Market Report by Drug Type, and Region 2025-2033

  • Report
  • 138 Pages
  • Global
From

About the Glioblastoma Drug Market

The Glioblastoma Drug market is a subset of the larger Brain Cancer Drug market. It is composed of drugs used to treat glioblastoma, a type of brain cancer. These drugs are typically used in combination with surgery, radiation, and chemotherapy to treat the disease. Common drugs used to treat glioblastoma include temozolomide, bevacizumab, and lomustine. These drugs are used to reduce tumor size, slow tumor growth, and reduce symptoms. The Glioblastoma Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Merck, Roche, Pfizer, and Bristol-Myers Squibb. Other companies in the market include Celgene, AstraZeneca, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.